Does administration of hydroxychloroquine/amiodarone affect the efficacy of enzyme replacement therapy for Fabry mice?

As a standard therapy for Fabry disease, enzyme replacement therapy (ERT) with recombinant human α-galactosidase A (α-Gal) has been successfully used, and the instructions for this drug state that “it should not be co-administrated with cationic amphiphilic drugs such as hydroxychloroquine (HCQ) and...

Descripció completa

Dades bibliogràfiques

Autors principals:	Takahiro Tsukimura, Koki Saito, Tomoko Shiga, Yasuhiro Ogawa, Hitoshi Sakuraba, Tadayasu Togawa
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-06-01
Col·lecció:	Molecular Genetics and Metabolism Reports
Matèries:	Fabry disease Drug-induced phospholipidosis Cationic amphiphilic drug Hydroxychloroquine Amiodarone Enzyme replacement therapy
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2214426924000326
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!